Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LPAR3 | Q9UBY5 | 14/20 | 0.69 |
| ▸ | LPAR2 | Q9HBW0 | 8/20 | 0.69 |
| ▸ | LPAR1 | Q92633 | 6/20 | 0.69 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.48 |
| ▸ | LPAR5 | Q9H1C0 | 1/20 | 0.47 |
| ▸ | LMNA | P02545 | 1/20 | 0.46 |
| ▸ | ESR1 | P03372 | 1/20 | 0.46 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.46 |
| ▸ | CDC25A | P30304 | 1/20 | 0.46 |
| ▸ | AGTR1 | P30556 | 1/20 | 0.46 |
| ▸ | AKT1 | P31749 | 1/20 | 0.46 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.46 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL482720 | 1.00 | LPAR3 (0.69) | LPAR3LPAR2LPAR1CYP3A4LPAR5 | |
| SCHEMBL11702476 | 1.00 | LPAR3 (0.69) | LPAR3LPAR2LPAR1CYP3A4LPAR5 | |
| SCHEMBL11699802 | 1.00 | LPAR3 (0.69) | LPAR3LPAR2LPAR1CYP3A4LPAR5 | |
| SCHEMBL11698797 | 1.00 | LPAR3 (0.69) | LPAR3LPAR2LPAR1CYP3A4LPAR5 | |
| SCHEMBL11699989 | 1.00 | LPAR3 (0.69) | LPAR3LPAR2LPAR1CYP3A4LPAR5 | |
| Thiophosphoric Acid Decyl Ester SCHEMBL194339 | 1.00 | LPAR3 (0.69) | LPAR3LPAR2LPAR1CYP3A4LPAR5 | |
| SCHEMBL11699523 | 1.00 | LPAR3 (0.69) | LPAR3LPAR2LPAR1CYP3A4LPAR5 | |
| Thiophosphoric Acid Tetradecyl Ester SCHEMBL193776 | 1.00 | LPAR3 (0.69) | LPAR3LPAR2LPAR1CYP3A4LPAR5 | |
| SCHEMBL1974387 | 1.00 | LPAR3 (0.69) | LPAR3LPAR2LPAR1CYP3A4LPAR5 | |
| SCHEMBL5965100 | 0.98 | LPAR3 (0.65) | LPAR3LPAR2LPAR1CYP3A4LPAR5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 74 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2481743-B1 | LPA receptor agonists and antagonists and methods of use | UNIV TENNESSEE RES FOUND (US) | 2017-03-22 | — | — | EP | claimed |
| EP-2433946-B1 | LPA receptor agonists and antagonists and methods of use | UNIV TENNESSEE RES FOUNDATION (US) | 2016-04-20 | — | — | EP | claimed |
| EP-2481743-A1 | LPA receptor agonists and antagonists and methods of use | UNIVERSITY OF TENNESSEE RESEARCH FOUNDATION (US) | 2012-08-01 | — | — | EP | claimed |
| EP-2433946-A1 | LPA receptor agonists and antagonists and methods of use | University of Tennessee Research Foundation (US) | 2012-03-28 | — | — | EP | claimed |
| EP-1906972-A2 | LPA2 RECEPTOR AGONIST INHIBITORS OF CFTR | The University of Tennessee Research Foundation (US) | 2008-04-09 | — | — | EP | claimed |
| US-20070078111-A1 | LPA2 receptor agonist inhibitors of CFTR | NATIONAL INSTITUTES OF HEALTH - DIRECTOR DEITR | 2007-04-05 | — | — | US | claimed |
| WO-2007011905-A2 | LPA2 RECEPTOR AGONIST INHIBITORS OF CFTR | THE UNIVERSITY OF TENNESSEE RESEARCH FOUNDATION (US) | 2007-01-25 | — | — | WO | claimed |
| US-20060009507-A1 | Thio-phosphoric and -phosphorous acid derivatives; treating cancer, wounds, skin disorders and apoptosis; preserving or restoring function in a cell, tissue or organ; culturing cells; preserving organ or tissue function; and enhancing cell proliferation | UNIVERSITY OF TENNESSEE RESEARCH FOUNDATION | 2006-01-12 | — | — | US | claimed |
| CN-119421940-A | Use of antiwear additives for increasing the thermal conductivity of cooling fluids for electric vehicles | 总和营销服务 | 2025-02-11 | — | — | CN | disclosed |
| US-20240336866-A1 | AQUEOUS LUBRICANT COMPOSITION FOR METALWORKING | TOTALENERGIES ONETECH (FR) | 2024-10-10 | — | — | US | disclosed |
| CN-117730136-A | Aqueous lubricating composition for metal working | 道达尔能源万泰克公司 | 2024-03-19 | — | — | CN | disclosed |
| CN-116264838-A | Oxidation-stable lubricant composition for motor vehicle transmission systems | 道达尔能源技术公司 | 2023-06-16 | — | — | CN | disclosed |
| CN-116194559-A | Lubricant composition for automotive transmission systems with improved corrosion resistance | 道达尔能源技术公司 | 2023-05-30 | — | — | CN | disclosed |
| CN-116171316-A | Lubricant composition for motor vehicle transmission systems | 道达尔能源技术公司 | 2023-05-26 | — | — | CN | disclosed |
| EP-1118654-A1 | FLUIDS FOR TRACTION DRIVE | Nippon Mitsubishi Oil Corporation (JP) | 2001-07-25 | — | — | EP | disclosed |
| US-6242393-B1 | NAPHTHENIC HYDROCARBONS, CARBOXYLATES OR CARBONATES FOR TRACTION | NIPPON MITSUBISHI OIL CORPORATION (JP) | 2001-06-05 | — | — | US | disclosed |
| US-6191330-B1 | SATURATED POLYCYCLIC HYDROCARBONS; AUTOMATIC TRANSMISSION | NIPPON MITSUBISHI OIL CORPORATION (JP) | 2001-02-20 | — | — | US | disclosed |
| EP-0989177-A1 | Traction drive fluid | Nippon Mitsubishi Oil Corporation (JP) | 2000-03-29 | — | — | EP | disclosed |
| EP-0949319-A2 | Traction drive fluid | Nippon Mitsubishi Oil Corporation (JP) | 1999-10-13 | — | — | EP | disclosed |
| US-4024049-A | Mono and di organophosphite esters as crude oil antifoulants | NALCO CHEMICAL COMPANY (US) | 1977-05-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060009507-A1 | Thio-phosphoric and -phosphorous acid derivatives; treating cancer, wounds, skin disorders and apoptosis; preserving or restoring function in a cell, tissue or organ; culturing cells; preserving organ or tissue function; and enhancing cell proliferation | LPAR1, LPAR6, LPAR2 | LPAR3 6/4885LPAR2 3/4885LPAR1 1/4885 |
| US-20070078111-A1 | LPA2 receptor agonist inhibitors of CFTR | LPAR2, NHERF1, LPAR1 | LPAR3 6/4885LPAR2 1/4885LPAR1 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.